A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Relapse Remitting Multiple Sclerosis
In brief
This was a randomized, partially blinded, placebo-controlled, non-confirmatory study to assess the effects of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis (RRMS).
Key facts
- Study ID
- NCT02038049
- Run by
- Novartis Pharmaceuticals
- People needed
- 8
- Starts
- 2013-12-20
- Expected to finish
- 2018-09-13
- Last updated by the study team
- 2021-01-05
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Long Beach, California, United States
- Novartis Investigative Site — San Diego, California, United States
- Novartis Investigative Site — Hradec Králové, Czechia
- Novartis Investigative Site — Kharkiv, Ukraine
- Novartis Investigative Site — Lviv, Ukraine
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.